Autologous cardiac progenitor stem cell therapy (Celyad)

N/A

Report date: 2025/03/14 13:37:25

Base Information

Drug NameAutologous cardiac progenitor stem cell therapy (Celyad)

Drug Alias NameC-CureCongestive heart failure cardiopoietic regenerative therapy (Celyad Oncology)Bone marrow derived mesenchymal cardiopoietic cells (Celyad Oncology)C3BS-CQR-1C3BR-CQR-1

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Cardiogenic potential stem cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsHeart Failure

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumBulgariaPoland +[9]

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCelyad

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCelyad Oncology SA

Active IndicationsN/A

Inactive IndicationsHeart Failure

Other Information

ATC CodeN/A